| Literature DB >> 26703552 |
Ling-Shang Wu1, Min Jia2, Ling Chen3, Bo Zhu4, Hong-Xiu Dong5, Jin-Ping Si6, Wei Peng7, Ting Han8,9.
Abstract
Two novel cytotoxic and antifungal constituents, (4S,6S)-6-[(1S,2R)-1, 2-dihydroxybutyl]-4-hydroxy-4-methoxytetrahydro-2H-pyran-2-one (1), (6S,2E)-6-hydroxy-3-methoxy-5-oxodec-2-enoic acid (2), together with three known compounds, LL-P880γ (3), LL-P880α (4), and Ergosta-5,7,22-trien-3b-ol (5) were isolated from the metabolites of endophytic fungi from Dendrobium officinale. The chemical structures were determined based on spectroscopic methods. All the isolated compounds 1-5 were evaluated by cytotoxicity and antifungal effects. Our present results indicated that compounds 1-4 showed notable anti-fungal activities (minimal inhibitory concentration (MIC) ≤ 50 μg/mL) for all the tested pathogens including Candida albicans, Cryptococcus neoformans, Trichophyton rubrum, Aspergillus fumigatus. In addition, compounds 1-4 possessed notable cytotoxcities against human cancer cell lines of HL-60 cells with the IC50 values of below 100 μM. Besides, compounds 1, 2, 4 and 5 showed strong cytotoxities on the LOVO cell line with the IC50 values were lower than 100 μM. In conclusion, our study suggested that endophytic fungi of D. officinale are great potential resources to discover novel agents for preventing or treating pathogens and tumors.Entities:
Keywords: Dendrobium officinale; antifungal activities; cytotoxic activities; endophytic fungi; metabolites
Mesh:
Substances:
Year: 2015 PMID: 26703552 PMCID: PMC6274016 DOI: 10.3390/molecules21010014
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Phylogenetic tree of the endophytic fungus DO14 based on 5.8S and ITS regions sequences. Bootstrap values above 50% (1000 replicates) are shown at branches. Nemania serpens is used as an out-group.
NMR data of compounds 1, 2.
| 1 a | 2 b | |||
|---|---|---|---|---|
| δC, Type | δH Mult ( | δC | δH Mult ( | |
| 2 | 171.9, C | 184.4, C | ||
| 3 | 41.6, CH2 | 2.88, dd (18.5, 2.3) | 105.8, CH | 5.63, s |
| 2.85, d (18.5) | ||||
| 4 | 97.1, C | 167.1, C | ||
| 5 | 29.3, CH2 | 2.44, dt (13.5, 2.3) | 36.5, CH2 | 3.55, 2H, s |
| 1.88, dd (13.5, 4.1) | ||||
| 6 | 78.7, CH | 4.74, m | 204.6, C | |
| 1′ | 66.8, CH | 3.51, m | 86.7, C | 4.46, dd (7.8, 4.2) |
| 2′ | 73.2, CH | 3.61, m | 30.7, CH2 | 1.88, m |
| 1.70, m | ||||
| 3′ | 33.7, CH2 | 1.70, m | 26.5, CH2 | 1.40, 2H, m |
| 1.56, m | ||||
| 4′ | 19.6, CH2 | 1.43, 2H, m | 22.3, CH | 1.34, 2H, m |
| 5′ | 14.3, CH3 | 0.95, t (7.3) | 13.8, CH3 | 0.89, t (7.3) |
| CH3O-4 | 49.2, CH3 | 3.36, s | 52.6, CH3 | 3.76, s |
in CD3OD. in CDCl.
Figure 2Selected 1H–1H COSY (━) and HMBC (→) correlations of 1 and 2.
Figure 3Supporting information of compound 1. (a) 1H-NMR of compound 1; (b) 13C-NMR and DEPT (Distortionless Enhancement by Polarization Transfer) of compound 1; (c) HSQC (Heteronuclear Multiple-Quantum Correlation) of compound 1; (d) 1H-1H COSY (correlated spectroscopy) of compound 1; (e) HMBC (Heteronuclear Multiple Bond Correlation) of compound 1; (f) NOESY of compound 1.
Figure 4Absolute configuration of compound 1. (a) CD spectrum of compound 3 in MeOH; (b) 1H-NMR spectrum of compound 1 in C5D5N; (c) 1H-NMR spectrum of compound 1 in CDCl3.
Figure 5Supporting information of compound 2. (a) 1H-NMR of compound 2; (b) 13C-NMR and DEPT of compound 2; (c) HSQC of compound 2; (d) 1H-1H COSY of compound 2; (e) HMBC of compound 2; (f) NOESY of compound 2.
Figure 6Structures of compounds 1–5.
Anti-fungal effects of compounds 1–5.
| MIC (μg/mL) | ||||
|---|---|---|---|---|
| 6.25 | 3.13 | 25 | 25 | |
| 12.5 | 12.5 | 6.25 | 3.13 | |
| 12.5 | 50 | 50 | 50 | |
| 6.25 | 3.13 | 50 | 25 | |
| >400 | 200 | >400 | >400 | |
| 0.0625 | 0.03125 | 0.5 | 1 | |
Ketoconazole (KTZ) was used as positive control.
Cytotoxic effects of compounds 1–5.
| IC50 (μM) | |||||
|---|---|---|---|---|---|
| MKN45 | LOVO | A549 | HepG2 | HL-60 | |
| 104.76 ± 5.34 | 50.97 ± 1.87 | 157.02 ± 2.01 | >200 | 15.24 ± 0.34 | |
| 135.87 ± 6.15 | 41.91 ± 1.07 | >200 | >200 | 30.09 ± 0.98 | |
| 125.87 ± 5.76 | 139.96 ± 5.76 | 182.92 ± 5.98 | >200 | 64.87 ± 1.47 | |
| 65.28 ± 1.98 | 68.88 ± 2.98 | 125.79 ± 4.07 | 191.68 ± 6.94 | 30.75 ± 1.65 | |
| >200 | 65.20 ± 1.37 | >200 | >200 | 171.54 ± 4.97 | |
| 0.14 ± 0.002 | 0.06 ± 0.002 | 0.16 ± 0.004 | 0.18 ± 0.004 | 0.01 ± 0.001 | |
Doxorubicin (DOX) was used as positive control.